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A B S T R A C T   
Statins are the low-density lipoproteins (LDL)-cholesterol-lowering drugs of first choice and are used to prevent 
the increased risk of cardiovascular and cerebrovascular diseases. Although some of their effects are well known, 
little is known about their ability to regulate other lipid-related proteins which control apoptotic mechanisms. 
The aim of this study was to explore whether statins can bind to cell death-inducing DNA fragmentation factor- 
like effector A (CIDEA), which might be a possible pleiotropic mechanism of action of these drugs on the 
modulation of apoptosis and lipid metabolism. The structures of statins were subjected to molecular docking and 
dynamics with the human CIDEA protein to investigate the interaction pattern and identify which residues are 
important. The docking results indicated that atorvastatin and rosuvastatin showed the best interaction energy 
(− 8.51 and − 8.04 kcal/mol, respectively) followed by fluvastatin (− 7.39), pitavastatin (− 6.5), lovastatin 
(− 6.23), pravastatin (− 6.04) and simvastatin (− 5.29). Atorvastatin and rosuvastatin were further subjected to 
molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower 
root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Since 
two arginine residues -ARG19 and ARG22-were identified to be common for the interaction with CIDEA, a single- 
point mutation was induced in these residues to determine whether they are important for binding interaction. 
Mutation of these two residues seemed to affect mostly the interaction of atorvastatin with CIDEA, suggesting 
that they are important for the binding and therefore indicate another possible metabolic mechanism of the 
pleiotropic effects of this statin.   
1. Introduction 
Cell death-inducing DNA fragmentation factor-like effector A 
(CIDEA) is a member of CIDE proteins family, which is composed of 
CIDEA, CIDEB and CIDEC/Fsp27. They are named so because the 
overexpression of CIDE proteins in different cell types induces caspase- 
independent cell death. The members of CIDE family are named 
according to their homology to the N-terminal domain of DNA frag-
mentation factor 40/45 (DFF40/45) [1,2]. CIDE proteins are connected 
with endoplasmic reticulum and lipid droplets and have emerged as 
important regulators of lipid homeostasis and the regulation of body 
weight. CIDEA is particularly expressed in the murine brown adipose 
tissue and human white adipose tissue [3], and much less in mammary 
glands [4], sebaceous glands in the skin [5], the meibomian glands [6], 
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and the brain [7]. CIDEA expression highly correlates with lipid storage, 
lipid secretion and fat metabolism in these tissues. 
There is not much data on plasma CIDEA and its association with 
plasma lipoproteins. In one small study on 28 patients, the highest mean 
relative expression of CIDEA gene occurred in patients with normal body 
weight and the lowest was in obese patients (BMI>30) with dyslipide-
mias [8]. It has been shown that CIDEB might control fatty acid synthesis 
and VLDL secretion in hepatocytes. In an animal experiment, hepatic 
cholesterol storage in the liver of CIDEB-null mice was significantly 
increased due to increased LDL receptors and acyl-CoA cholesterol 
acyltransferase (ACAT) expression while cholesterol levels were drasti-
cally reduced in the heart of CIDEB-null mice fed with a high cholesterol 
diet [9]. 
Statins are the cornerstone of treatment for patients with elevated 
low-density lipoprotein (LDL)-cholesterol who are at an increased risk of 
atherosclerotic cardiovascular and cerebrovascular diseases [10–12]. 
However, apart from lowering LDL-cholesterol, statins have other 
beneficial pleiotropic effects which are independent of their 
LDL-cholesterol-lowering effect, including anti-inflammatory, antith-
rombotic, antioxidant effects, and improvement of endothelial and brain 
function [13–21]. They also induce cell apoptosis, which is considered 
to be a beneficial effect as well [22,23]. Taking together the findings of 
all the previous studies, modulation of CIDEA might be considered as an 
important target to maintain lipid homeostasis and controlled apoptosis. 
The aim of this study was to explore whether statins can bind with 
CIDEA, which might be a possible mechanism of action of these drugs for 
the modulation of apoptosis and lipid metabolism. 
2. Materials and methods 
The bioinformatics tools Molecular Operating Environment (MOE 
version 2015), Visual Molecular Dynamics (VMD), Swiss PDB viewer, 
Autock Vina, CASTp server (http://sts.bioe.uic.edu/castp) were used to 
analyse the data. All the 3D structures of atorvastatin (CID: 60823), 
rosuvastatin (CID: 446157), fluvastatin (CID: 446155), pitavastatin 
(CID: 5282452), lovastatin (CID: 52232), pravastatin (CID: 54687), and 
simvastatin (CID: 54454) were downloaded from Pubchem database 
(https://pubchem.ncbi.nlm.nih.gov/). Polar hydrogens and charges 
were added before docking. The human CIDEA solution structure was 
downloaded from the Protein Database (Entry PDB: 2EEL). The protein 
structure was prepared using the “Structure preparation” plugin in MOE 
for protonation and energy minimization, the protein-associated ligands 
were removed, and the missing hydrogen atoms were added. 
2.1. Molecular docking 
To determine the orientation of the respective ligands at the CIDEA 
active site, we used the MOE program. The preparation of the protein 
(CIDEA) was performed with elimination of ligands or other ions, as well 
as the water atoms before performing energy minimization using the 
plugin in MOE. The sitefinder plugin was used to determine the potential 
active sites of the protein, which was subsequently confirmed and 
validated by the online server CASTp 3.0. MOE Builder prepared the 
molecular structures of atorvastatin, rosuvastatin, fluvastatin, pit-
avastatin, lovastatin, pravastatin, and simvastatin using Hamiltonian- 
Force Field-MMFF94x. For docking, the default MOE dock setting (80 
different poses for a final refinement of 5) was used. To determine the 
best conformations of the different interactions, we used the scores 
London dG and GBVI/WSA dG, which is an estimate of free energy based 
on the force field from a pose between the ligand and the protein. 
Validation of docking poses was assessed using Autock Vina on PyRx 
software. The best poses were found, scored, and selected for molecular 
dynamics studies. 
2.2. Molecular dynamics simulation 
The molecular dynamics (MD) studies between CIDEA and the li-
gands with the best confirmations observed from the docking results 
were assessed under physiological conditions at T = 37C and P = 1ATM. 
We used the Simulation-Dynamics plugin in MOE and the results of the 
trajectory were analysed with the VMD (https://www.ks.uiuc.edu/Rese 
arch/vmd/). The topology parameters for the selected substances were 
generated by the PRODRG server and the systems were immersed in the 
center of a water box to stimulate the aqueous environment. The algo-
rithm used was the NPA (Noise-Poincare-Anderson equation), which is 
quite sensitive, with a cut-off of 9.10 R-field of 1:80, and an Amber 10: 
EHT force field. A minimization of energy for 1500 steps descent before 
equilibration at 300 K was set. The system’s temperature increased from 
0 to 300 k during the equilibration period of 100 ps, a period during 
which it was kept at constant pressure. Finally, the 50ns MD simulations 
were performed with a time step of 2 fs, and the trajectory of the system 
was stored every 10ps and analysed by VMD to determine the root- 
mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), 
the number of hydrogen bonds (H-bonds) and radius of gyration (Rgyr). 
2.3. Mutagenesis study 
To produce a single-point mutation in residues which may have an 
essential role in the interaction between CIDEA and statins, by using the 
MOE program we induced the following amino acids substitutions: 
ARG19 by PRO19 and ARG22 by ASN22. The mutant structures were 
analysed by Swiss PDB viewer to determine the impact of these point 
mutations on protein structure. Parameters such electrostatic potential 
energy (E_ele), solvation energy (E_sol), energy of the highest occupied 
molecular orbital (HOMO), energy of the lowest unoccupied molecular 
orbital (LUMO), water accessible surface area (ASA), van der Waals 
surface area (VSA) and potential energy (E) were assessed to explore the 
implication of these mutations for the interaction of atorvastatin and 
rosuvastatin with CIDEA. 
3. Results 
3.1. Docking analysis of statins and human CIDEA 
With a size of 91 residues (atom count 681) and a single chain (A), 
the human CIDEA (PDB: 2EEL) solution structure of the CIDE-N domain 
of the complete protein (CIDEA) was used. Among the 20 conformers 
submitted, the one with the lowest number of restraint violations with 
lowest energy was chosen for the analysis of docking and molecular 
dynamics. To locate the binding pocket of CIDEA, we initially used the 
sitefinder plugin in MOE, which was later confirmed by the CASTp 
server [24], where it showed that the residues SER15, ASP18, ARG9, 
SER20, SER21, ARG22, HIS73, SER86, GLY87, SER89, and SER90 are 
parts of the active protein interaction site. Based on the docking analysis 
of the interaction between CIDEA and statins, atorvastatin had the 
lowest interaction energy (− 8.51 kcal/mol), followed by rosuvastatin 
(− 8.04 kcal/mol), fluvastatin (− 7.39 kcal/mol), pitavastatin (− 6.5 
kcal/mol), lovastatin (− 6.23 kcal/mol), pravastatin (− 6.04 kcal/mol) 
and finally simvastatin (− 5.29 kcal/mol) (Table 1). The ligands inter-
acting with CIDEA which had the lowest solvation energy were ator-
vastatin (− 52.35 kcal/mol) and rosuvastatin (− 54.39 kcal/mol). 
Atorvastatin-CIDEA complex (Fig. 1A–B) formed 6 hydrogen bonds 
(as donor or acceptor) with ASP18, SER86, ARG19 and ARG22, the latter 
having the lowest binding interaction (− 10.1 kcal/mol) together with 
ARG19 (− 9.6 kcal/mol). Similarly, this statin interacted with CIDEA 
also by ionic bonds at residues ARG22 and ARG19 (Suppl Table 1). For 
rosuvastatin-CIDEA complex (Fig. 2A–B), the interaction occurred 
exclusively through residues ARG19 and ARG22, where 4 hydrogen 
bonds as acceptors and 4 ionic bonds are formed, with binding energy 
between − 10.3 kcal/mol for NH2 of ARG22 at 2.77 A and − 9.2 kcal/mol 
G.E. Barreto et al.                                                                                                                                                                                                                              
Chemico-Biological Interactions 345 (2021) 109528
3
for NH2 of ARG19 also at 2.77 A. We have found that there is a pattern of 
interaction of these statins with CIDEA that occurred on NH2 by 
hydrogen bonds at residues ARG19 (fluvastatin: 8.1 kcal/mol; pit-
avastatin: 9.7 kcal/mol) and ARG22 (fluvastatin: 10.3 kcal/mol; pit-
avastatin: 10.5 kcal/mol) and ionic bonds in ARG22 (pravastatin: 7.8 
kcal/mol). The 2D representations of other statins are displayed in 
Suppl. Fig 1. Overall, these results suggest that possibly the binding of 
atorvastatin and rosuvastatin with CIDEA occurred mainly through 
these residues. 
3.2. Molecular dynamics assessment 
Among the docked interactions previously explored, considering 
both binding and solvation energies, we shortlisted the ligands ator-
vastatin and rosuvastatin to evaluate more precisely how they interacted 
with CIDEA using molecular dynamics at 50 ns Since the molecular 
conformation of a protein can change after binding with a ligand, we 
determined the root-mean-square deviation (RMSD), which is a 
parameter that measures the deviation of the protein structure, as well 
as its stability after binding with other proteins/ligands. Both complexes 
(atorvastatin-CIDEA and rosuvastatin-CIDEA) showed a good overall 
stability at 50 ns (Fig. 3A). The averaged RMSD of both complexes were 
quite similar (0.112 ± 0.01 and 0.109 ± 0.01 for CIDEA-Atorvastatin 
and CIDEA-Rosuvastatin, respectively; Table 2). However, from the 
33ns of MD, the complexes diverged from each other and the 
rosuvastatin-CIDEA complex seemed to be more stable and with less 
deviation compared to atorvastatin-CIDEA complex (Table 2). This is 
also reflected on the averaged binding energy between the two com-
plexes. Rosuvastatin showed a better interaction with CIDEA in this 
parameter (− 418.538 ± 13.61 kcal/mol; Table 2). During the MD at 
50ns we calculated the RMSF (root-mean-square fluctuation), which 
indicates the flexibility of a specific atom when the structures are 
superimposed, in other words it indicates the flexibility of a residue 
during the interaction (Fig. 3B). The RMSF plot showed fluctuations of 
some residues in the different regions of CIDEA. We found a lower value 
in RMSF of CIDEA when bound to rosuvastatin (0.045 ± 0.09, Table 2) 
when compared with that of atorvastatin (0.054 ± 0.08). During the 
simulation, the number of hydrogen bonds (Fig. 3C) that are formed was 
calculated and we observed that atorvastatin forms more bonds with 
CIDEA when compared with rosuvastatin (6.187 ± 0.98 vs 5.987 ± 0.86; 
Table 2). Finally, we assessed the gyrus of gyration that indicates the 
protein stability and compactness during the simulation. In Fig. 3D, the 
plot showed some fluctuations in the rosuvastatin-CIDEA complex, 
which then stabilized after 17 ns On the other hand, the atorvastatin- 
CIDEA interaction showed an increase in fluctuation from the 33ns 
Table 1 
Docking results showing the binding energy, solvation energy and interaction 
residues of human CIDEA with statins.  





Atorvastatin − 8.51 − 52.35 ASP18, SER86, 
ARG19, ARG22 
Rosuvastatin − 8.04 − 54.39 ARG19, ARG22 
Fluvastatin − 7.39 − 50.1 ARG19, ARG22 
Pitavastatin − 6.5 − 44.94 GLY87, ARG19, 
ARG22 
Lovastatin − 6.23 − 34.35 ARG19, SER86 
Pravastatin − 6.04 − 35.7 SER90, ARG19, 
ARG22 
Simvastatin − 5.29 − 23.33 PRO85  
Fig. 1. Structural representation of human CIDEA complexed with Aatorvastatin. 2D (A) and 3D (B) schematic showing the binding interaction.  
Fig. 2. Docked complex interaction between rosuvastatin and human CIDEA. 2D (A) and 3D (B) representation of the binding interaction.  
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and has a conformational shift when compared with the other complex. 
It must be stressed that concerning this parameter the more fluctuations, 
the lower is the stability of the complex. Although the trajectories of 
both complexes indicated some discrepancies, taken in general, the 
complexes behaved similarly and demonstrated an averaged Rgyr of 
13.191 (atorvastatin) and 13.170 (rosuvastatin) (Table 2). 
3.3. ARG19 and ARG22 implications in the binding of atorvastatin and 
rosuvastatin with CIDEA 
Because we identified that ARG19 and ARG22 are common residues 
and may be involved in the interaction of atorvastatin and rosuvastatin 
with CIDEA, we performed a single mutation (amino acid substitution) 
on these residues. The ARG19 residue was mutated to PRO19, while the 
ARG22 residue was mutated to ASN22. These mutations did not produce 
any significant alterations in the CIDEA structure and conformation. 
After performing these mutations, we ran a molecular docking between 
atorvastatin and rosuvastatin with CIDEA under different conforma-
tions: CIDEAcontrol (original protein), CIDEARG19 (ARG19→PRO19), 
CIDEAARG22 (ARG22→ASN22) and CIDEAARG19/22 (both mutations) and 
several structural and energetic parameters were calculated. Taken in 
general, mutation of both residues ARG19 and ARG22 seemed to affect 
mostly the atorvastatin-CIDEA complex, since we have observed an in-
crease in RMSD, a decrease in E and slightly alterations in the ability to 
accept and donor electrons (HOMO and LUMO) (Table 3). 
4. Discussion 
In this study, an in silico molecular docking experiment and dynamics 
estimation on the interaction of different statins with CIDEA was 
Fig. 3. Molecular dynamics simulation of atorvastatin and rosuvastatin with CIDEA. Evaluation of root-mean square deviation (RMSD, A), root-mean square 
fluctuation (RMSF, B), H-bonds (C) and radius of gyration during 50ns simulation. Blue lines represent Atorvastatin-CIDEA complex while red lines are Rosuvastatin- 
CIDEA complex. 
Table 2 
Average of systematic molecular dynamics (MD) parameters. Root-mean square deviation (in angstrom), root-mean square fluctuation (in angstrom), the number h- 
bonds and radius of gyration (rgyr) were further assessed for the best conformations selected from docking results.  
Complex Binding energy (kcal/mol) RMSD (A) RMSF (A) H-bonds (number) Rgyr 
CIDEA-Atorvastatin − 307.402 ± 15.55 0.112 ± 0.01 0.054 ± 0.08 6.187 ± 0.98 13.191 ± 0.01 
CIDEA-Rosuvastatin − 418.538 ± 13.61 0.109 ± 0.01 0.045 ± 0.09 5.987 ± 0.86 13.170 ± 0.01  
Table 3 
Mutation studies of Atorvastatin and Rosuvastatin-CIDEA interactions. ARG19 and ARG22 residues were substituted to PRO19 and ASN22, respectively. Three 
additional protein conformations were estimated: CIDEAARG19, CIDEAARG22 and CIDEAARG19/22, besides the original protein (CIDEAcontrol).  
Parameters CIDEAcontrol CIDEAARG19 CIDEAARG22 CIDEAARG19/22  
Atorvastatin Rosuvastatin Atorvastatin Rosuvastatin Atorvastatin Rosuvastatin Atorvastatin Rosuvastatin 
E_ele − 77.636 − 152.76 − 79.391 − 146.415 − 80.048 − 157.283 − 82.336 − 147.545 
E_sol − 91.743 − 114.866 − 93.043 − 121.577 − 92.084 − 106.107 − 94.725 − 120.824 
HOMO − 4.728 − 4.615 − 4.682 − 4.583 − 4.683 − 4.568 − 4.67 − 4.506 
LUMO 1.22 − 0.587 1.304 − 0.538 1.234 − 0.543 1.179 − 0.563 
ASA 834.302 710.573 830.228 716.383 835.547 711.322 829.588 716.998 
VSA 579.199 478.97 580.134 484.435 577.414 479.311 578.714 482.397 
E 13.661 − 46.804 13.05 − 42.202 12.905 − 54.451 6.602 − 42.837 
RMSD 1.805 1.908 2.028 1.933 2.082 1.694 2.127 1.709 
Abbreviations: Electrostatic potential energy (E_ele), solvation energy (E_sol), energy of the highest occupied molecular orbital (HOMO), energy of the lowest un-
occupied molecular orbital (LUMO), water accessible surface area (ASA), van der Waals surface area (VSA) and potential energy (E). 
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performed. The rationale behind this experiment was some indications 
that CIDEA is not only involved in lipid storage, but also in lipid 
secretion. Statins are the most widely used LDL-cholesterol lowering 
drugs and they work primarily by inhibiting the activity of the enzyme 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in 
various tissues, including the brain. This enzyme is essential for 
endogenous synthesis of cholesterol and its inhibition by statins in-
creases the number of LDL receptors and increases the elimination of 
cholesterol-rich LDL particles from the blood. We also aimed to inves-
tigate the interaction pattern and identify which residues are important 
for this process. The results indicated that atorvastatin and rosuvastatin 
showed the greatest interaction with CIDEA. 
Docking studies may be of great value because until now no studies 
have investigated the direct molecular interactions between statins and 
CIDEA. We have recently shown by using this approach that statins, and 
particularly pitavastatin, might directly affect the SARS-CoV-2 virus 
particle and therefore could be useful in COVID-19 treatment [25]. 
Kumar et al. have also recently shown using in silico method that sim-
vastatin could interact with endocan, which is a cardiovascular in-
flammatory biomarker elevated in atherosclerosis that may play a role in 
atherogenesis by activating macrophages [26]. A recent molecular 
docking report also identified specific compounds in melatonin-rich and 
1,8-cineole-rich extracts obtained from yellow mustard and small 
cardamom seeds, which had binding affinities comparable with statins 
[27]. Already several years ago a study indicated that polyphenolic 
moieties might be potential lipid-lowering agents by inhibiting HMG 
CoA reductase in an in silico model [28]. More recently it has been shown 
in silico that the phenolic derivative 4a had strong binding activity 
against human HMG-Co-A [29]. Finally, a docking study screened some 
natural compounds to bind the fatty acid binding protein 5 (FABP5), 
another lipid-related protein, indicating that pteroyl-L-glutamate had 
the most favourable interaction, thus suggesting a possible modulation 
of lipid metabolism by this ligand [30]. 
Although the use of statins as regulators of lipid metabolism is 
acknowledged, their clinical use is to a certain extent still controversial. 
By interacting with CIDEA atorvastatin may regulate lipid dysregulation 
(see results section), in addition to reducing IL-6 levels [31], amyloid-β 
(Aβ)-induced microglia activation and the release of pro-inflammatory 
MCP-1 and IP-10 [32] and downregulation of TRAF6 and TLR4 [33] 
in brain cells, while attenuating IFN-γ and IL-6 and chemokines IP-10 
and RANTES but stimulating IL-10 and TGF-β1 following traumatic 
brain injury [34]. The fact that atorvastatin binds to amyloid-β (Aβ) [14] 
demonstrates its ability to regulate neuroinflammation by inhibiting 
IFN-γ [32], IL-β [35], and NF-kB [33,36], while producing an increase in 
anti-inflammatory IL-4 in rat brain [35], a similar result observed with 
rosuvastatin [15,37]. On the other hand, there were some indications 
that statins, in particular atorvastatin, could induce cyto- and genotox-
icity [38–40]. According to some authors, it seems that atorvastatin after 
long-term exposure in its highest dose might be capable of producing 
damage on the level of DNA molecule [39,41]. However, according to 
some other studies atorvastatin, similarly to other tested HMG-CoA 
reductase inhibitors, does not seem to be genotoxic [38]. On the con-
trary, there are reports showing that statins can act as antimutagenic, 
antigenotoxic, and cytoprotective substances, specifically against alky-
lating agents of DNA [42]. Most of the information about possible 
cytotoxic mechanisms of statins comes from cell cultures and experi-
mental animal studies and suggests that these mechanisms might be 
predominantly associated with oxidative stress since statin-induced 
metabolism involves various CYP450 enzymes, which provide poten-
tial sites for statin-induced oxidative stress [40]. Statins can express 
their cytotoxicity via the mitochondrial pathway, as evidenced by 
decreased mitochondrial membrane potential, and elevated calcium 
release, mitochondrial mass, and cell apoptosis, as well as reactive ox-
ygen species [43]. In clinical practice, there is less concern over the 
safety of statins and there are reports showing antioxidant effects [16] 
and therapeutic effects via affecting mitochondrial pathways [44]. 
Because rosuvastatin may induce epigenetic modifications in newborns, 
its use by pregnant women is not advisable [45]. 
As already mentioned, this is the first study analyzing the interaction 
between statins and human CIDEA. We found that the binding of ator-
vastatin and rosuvastatin with CIDEA occurs mainly through two argi-
nine residues, ARG19 and ARG22, which has not been described before. 
Mutation of these two residues seems to affect mostly the interaction of 
atorvastatin with CIDEA, suggesting that they are important for this 
binding and therefore suggesting a possible mechanism of some pleio-
tropic effects, at least of this statin. The limitation of this study is in its in 
silico nature. Therefore, our results need to be confirmed by experi-
mental studies on animals, which might support our findings, as well as 
studies in patients with dyslipidemia and/or cerebrovascular diseases 
treated with statins. Pharmacogenetic studies are also needed to explore 
whether inter-individual variations as a response to statin therapy might 
be, at least in part, attributed to CIDEA or related proteins. 
5. Conclusions 
The results of this molecular docking study indicated that atorvas-
tatin and rosuvastatin showed the best interaction energy with CIDEA, 
followed by fluvastatin, pitavastatin, lovastatin, pravastatin and sim-
vastatin. Rosuvastatin-CIDEA complex had lower RMSD, RMSF and less 
fluctuations when compared with atorvastatin-CIDEA complex. Muta-
tion of amino acids ARG19 and ARG22 residues seemed to affect mostly 
the interaction of atorvastatin with CIDEA, suggesting that they are 
important for the interaction of this statin with CIDEA. This might 
explain a possible mechanism of some pleiotropic effects, at least of this 
statin. 
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